Athersys (ATHX) : During the past 4 weeks, traders have been relatively bearish on Athersys (ATHX), hence the stock is down -14.6% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.93% relative to the S&P 500. The 4-week change in the price of the stock is -13.72% and the stock has fallen -8.88% in the past 1 week.
The stock has recorded a 20-day Moving Average of 8.94% and the 50-Day Moving Average is 11.14%. Athersys (NASDAQ:ATHX): On Fridays trading session , Opening price of the stock was $1.95 with an intraday high of $1.97. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $1.88. However, the stock managed to close at $1.95, a loss of 0.51% for the day. On the previous day, the stock had closed at $1.96. The total traded volume of the day was 1,059,963 shares.
The company Insiders own 6% of Athersys shares according to the proxy statements. Institutional Investors own 12.56% of Athersys shares. During last six month period, the net percent change held by insiders has seen a change of -7.82%.
Athersys Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Companys MultiStem cell therapy is being evaluated in multiple clinical trials. Its current clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease and other conditions. It is also identifying and developing small molecule compounds with applications in indications, such as obesity, related metabolic conditions and neurological conditions. It is engaged in the preparation stages for clinical studies in other targeted areas, including the treatment of ARDS. Its current programs include Ischemic Stroke, Acute Myocardial Infarction, Acute Respiratory Distress Syndrome, Hematopoietic Stem Cell Transplant/GvHD and Inflammatory Bowel Disease. In addition to the programs, it is also conducting or supporting clinical activity in other areas, such as solid organ transplant.